Management and Board Have Funded More than $11M to Support Growth Management and Board Have Funded More than $11M to Support Growth
Originally posted here:
Better Choice Announces Closing of Expanded Series F Financing and Acceleration of Asian Expansion
VALENCIA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option.
Read the original here:
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award, sweeping the CRO category for the fourth consecutive year. Presented at SCRS’s Global Site Solutions Summit, the award recognizes the CRO that best exemplifies a site-focused approach to clinical trial management, demonstrating outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.
Read the original here:
Syneos Health Wins Society for Clinical Research Sites Eagle Award for Fourth Consecutive Year
BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead asset, mavorixafor, for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene.
Read the original post:
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
See the article here:
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch...
? Clear Development Path Forward for XRx-101 ? ? Clear Development Path Forward for XRx-101 ?
Excerpt from:
XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Go here to see the original:
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in...
MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will be a participant on the panel titled “Emerging Companies” at the Targeting Metabesity Conference, being held virtually on October 12-15, 2020. A live webcast of the presentation will be available for attendees who register at http://www.metabesity2020.com/register.html. Viewing is complimentary.
See the article here:
CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference
WATERTOWN, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public offering of 11.04 million shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1.44 million additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to C4T from the offering were $209.76 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by C4T.
The rest is here:
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares